* The leukemia drug Sprycel could potentially increase the risk of pulmonary arterial hypertension (PAH), the FDA warned. Sprycel, a drug made by Bristol-Myers Squibb Co., was approved for use in the United States in 2006, but several cases of PAH linked to use of the drug have been reported since then.* No fatal cases have been reported. According to the FDA, Sprycel will begin to carry a ...